Clinical-stage biotech advancing ATH434 for Multiple System Atrophy (MSA). Positive Phase 2 results. FDA-aligned Phase 3 program. ASX: ATH, NASDAQ: ATHE
Joined April 2019
- Tweets459
- Following119
- Followers304
- Likes485
Clinical-stage biotech advancing ATH434 for Multiple System Atrophy (MSA). Positive Phase 2 results. FDA-aligned Phase 3 program. ASX: ATH, NASDAQ: ATHE